Active Ingredient(s): Necitumumab
FDA Approved: * November 24, 2015
Pharm Company: * ELI LILLY CO
Category: Cancer

Necitumumab (INN) is a recombinant human IgG1 monoclonal antibody used as an antineoplastic, which is manufactured by Eli Lilly. It binds to the epidermal growth factor receptor (EGFR).[1] The US FDA approved necitumumab under the brand name Portrazza for use with gemcitabine and cisplatin in previously untreated metastatic squamous non-small-cell lung carcinoma (NSCLC).[2][3][4] It was counterproductive in non-squamous non-sma... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Portrazza 16 mg/ml Intravenous Solution
NDC: 0002-7716
Eli Lilly and Company